Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 128Melanoma 90Squamous Cell Carcinoma of Head and Neck 88Breast Neoplasms 70Triple Negative Breast Neoplasms 63Parkinson Disease 4, Autosomal Dominant Lewy Body 45Head and Neck Neoplasms 45Lung Neoplasms 38Ovarian Neoplasms 37Neoplasms 37Neoplasm Metastasis 37Colorectal Neoplasms 37Stomach Neoplasms 36Carcinoma, Renal Cell 34Carcinoma, Transitional Cell 31Pancreatic Neoplasms 29Urinary Bladder Neoplasms 28Carcinoma, Hepatocellular 27Recurrence 21Hodgkin Disease 21Uterine Cervical Neoplasms 20Endometrial Neoplasms 20Prostatic Neoplasms 18Esophageal Neoplasms 18Sarcoma 17Glioblastoma 17Brain Neoplasms 16Fallopian Tube Neoplasms 15Esophageal Squamous Cell Carcinoma 15Carcinoma, Squamous Cell 14

Interventions

enzalutamide 3Abiraterone Acetate 2testosterone enanthate 1pembrolizumab 1disitamab vedotin 1abiraterone 1Radium-223 1Prednisone 1Ketoconazole 1Hydrocortisone 1Flutamide 1Calcitriol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Castration-resistant Prostate Cancer × pembrolizumab × Clear all
NCT03506997 2020-07-22

PERSEUS1

Institute of Cancer Research, United Kingdom

Phase 2 Unknown
100 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡